Pandemic News

Drug Safety Newsletter on Antivirals

September 02, 2009

The IMB has published a Drug Safety Newsletter on the antiviral medicines Tamiflu and Relenza, which provides an overview of relevant regulatory activities and associated recommendations for safe use of these medicines.

The IMB has developed a web-based system for reporting of adverse reactions by healthcare professionals, patients and the public during the pandemic. This is accessible via a designated ‘pandemic webpage' on the IMB website at

Please use the contact details below with any queries you may have in relation to the newsletter or the reporting of adverse reactions:

Tel: 353-1-676 4971
Fax: 353-1-634 3514

Pharmacovigilance Section,
Irish Medicines Board,
Kevin O'Malley House,
Earlsfort Centre,
Earlsfort Terrace,
Dublin 2,

Back to News List